Xeloda plus chemo reduces recurrence 34%
Data from a new study of Roche's Xeloda (capecitabine) plus standard chemotherapy show that the combination allows women to live cancer-free for longer.
The Swiss drug major presented preliminary data at this year's San Antonio Breast Cancer Symposium demonstrating that women with early breast cancer taking Xeloda as part of their chemotherapy had a 34% reduction in the risk of the disease returning.
The trial by the Finnish Breast Cancer Group carried out in Finland and Sweden also showed that patients in the Xeloda arm were more likely to live longer overall and less likely to have their cancer spread to another part of the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze